Technical Analysis for AQST - Aquestive Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 5.51 | -9.52% | -0.58 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Very Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week High | Strength | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
New 52 Week Closing High | Bullish | -9.52% | |
180 Bullish Setup | Bullish Swing Setup | -9.52% | |
Pocket Pivot | Bullish Swing Setup | -9.52% | |
Volume Surge | Other | -9.52% | |
New 52 Week High | Strength | -9.52% | |
Wide Bands | Range Expansion | -9.52% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 20 hours ago |
2x Volume Pace | about 22 hours ago |
1.5x Volume Pace | about 22 hours ago |
Down 5% | about 22 hours ago |
Down 3% | about 22 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 04/30/2024
Aquestive Therapeutics, Inc. Description
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Disease Drugs Psychoactive Drugs Opioids Epilepsy Amyotrophic Lateral Sclerosis Chloroarenes Seizure Gabaa Receptor Positive Allosteric Modulators Neuroendocrine Tumor Neuroendocrine Tumors Anaphylaxis Parkinson’s Disease Riluzole
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 6.23 |
52 Week Low | 0.7805 |
Average Volume | 1,850,150 |
200-Day Moving Average | 2.15 |
50-Day Moving Average | 3.23 |
20-Day Moving Average | 4.21 |
10-Day Moving Average | 5.21 |
Average True Range | 0.55 |
RSI (14) | 66.56 |
ADX | 66.92 |
+DI | 34.40 |
-DI | 2.54 |
Chandelier Exit (Long, 3 ATRs) | 4.58 |
Chandelier Exit (Short, 3 ATRs) | 4.10 |
Upper Bollinger Bands | 6.51 |
Lower Bollinger Band | 1.91 |
Percent B (%b) | 0.78 |
BandWidth | 109.11 |
MACD Line | 0.76 |
MACD Signal Line | 0.65 |
MACD Histogram | 0.1174 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 6.59 | ||||
Resistance 3 (R3) | 6.71 | 6.47 | 6.41 | ||
Resistance 2 (R2) | 6.47 | 6.19 | 6.41 | 6.35 | |
Resistance 1 (R1) | 5.99 | 6.03 | 5.87 | 5.87 | 6.29 |
Pivot Point | 5.75 | 5.75 | 5.69 | 5.69 | 5.75 |
Support 1 (S1) | 5.27 | 5.47 | 5.15 | 5.15 | 4.73 |
Support 2 (S2) | 5.03 | 5.31 | 4.97 | 4.67 | |
Support 3 (S3) | 4.55 | 5.03 | 4.61 | ||
Support 4 (S4) | 4.43 |